Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNYSE:BKDNYSE:CLINYSEARCA:FBT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.47+8.1%$9.41$2.09▼$14.84$489.89M0.053.66 million shs2.34 million shsBKDBrookdale Senior Living$6.58+1.5%$6.20$3.33▼$7.05$1.23B1.321.81 million shs1.73 million shsCLIMack-Cali Realty$18.21$11.74▼$19.90$1.67B1.03658,571 shs65,804 shsFBTFirst Trust NYSE Arca Biotechnology Index Fund$142.93+0.9%$150.95$130.27▼$161.41$1.09B0.8528,770 shs18,923 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+8.10%-1.06%-17.73%-25.45%+29.02%BKDBrookdale Senior Living+1.54%+4.03%+2.17%+9.03%+54.10%CLIMack-Cali Realty0.00%0.00%0.00%0.00%0.00%FBTFirst Trust NYSE Arca Biotechnology Index Fund+0.88%-1.45%-6.69%-6.56%-9.50%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.5967 of 5 stars3.32.00.00.03.21.70.0BKDBrookdale Senior Living3.2053 of 5 stars2.32.00.04.92.31.70.6CLIMack-Cali RealtyN/AN/AN/AN/AN/AN/AN/AN/AFBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.67Moderate Buy$15.00100.80% UpsideBKDBrookdale Senior Living2.50Moderate Buy$7.5013.98% UpsideCLIMack-Cali RealtyN/AN/AN/AN/AFBTFirst Trust NYSE Arca Biotechnology Index Fund0.00N/A$192.1334.42% UpsideCurrent Analyst RatingsLatest ALT, BKD, CLI, FBT, and ID8 Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024BKDBrookdale Senior LivingRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,231.51N/AN/A$2.75 per share2.72BKDBrookdale Senior Living$3.02B0.41$0.87 per share7.59$2.15 per share3.06CLIMack-Cali Realty$313.56M0.00N/AN/A$17.55 per share0.00FBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)BKDBrookdale Senior Living-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/13/2024 (Estimated)CLIMack-Cali Realty-$51.39M-$0.41N/A0.002.58-8.54%-7.28%-2.31%N/AFBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/A16.52∞N/AN/AN/AN/AN/ALatest ALT, BKD, CLI, FBT, and ID8 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 million2/20/2024Q4 2023BKDBrookdale Senior Living-$0.19-$0.40-$0.21-$0.40N/A$754.48 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ABKDBrookdale Senior LivingN/AN/AN/AN/AN/ACLIMack-Cali RealtyN/AN/AN/AN/AN/AFBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A17.2617.26BKDBrookdale Senior Living9.400.800.80CLIMack-Cali Realty1.610.720.72FBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%BKDBrookdale Senior LivingN/ACLIMack-Cali Realty86.77%FBTFirst Trust NYSE Arca Biotechnology Index FundN/AInsider OwnershipCompanyInsider OwnershipALTAltimmune4.10%BKDBrookdale Senior Living1.50%CLIMack-Cali Realty5.70%FBTFirst Trust NYSE Arca Biotechnology Index FundN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5970.89 million67.99 millionOptionableBKDBrookdale Senior Living25,200189.34 million186.50 millionOptionableCLIMack-Cali Realty2,01890.95 million85.76 millionOptionableFBTFirst Trust NYSE Arca Biotechnology Index FundN/A7.60 millionN/ANot OptionableALT, BKD, CLI, FBT, and ID8 HeadlinesSourceHeadlineIs First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?zacks.com - April 9 at 7:21 AMShould You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?zacks.com - April 1 at 7:21 AMFirst Trust NYSE Arca Biotechnology Index Fund (FBT)finance.yahoo.com - March 31 at 4:22 AMClosing Bell: First Trust NYSE Arca Biotechnology ETF up on Friday (FBT)theglobeandmail.com - January 6 at 1:41 PMClosing Bell: First Trust NYSE Arca Biotechnology ETF flat on Friday (FBT)theglobeandmail.com - January 6 at 1:41 PMFirst Trust Dynamic Europe Equity Income Fund Declares its Monthly Common Share Distribution of $0.07 Per Share for Novemberbenzinga.com - October 23 at 5:34 PMNYSE Arca Major Market Indexwsj.com - September 29 at 12:33 AMFBT First Trust NYSE Arca Biotechnology Index Fund ETFseekingalpha.com - April 27 at 10:23 AMNYSE Arca Securities Broker/Dealer Indexwsj.com - March 17 at 5:39 PMNYSE Arca Gold BUGS Indexwsj.com - March 11 at 6:50 PMFirst Trust NYSE Arca Biotechnology Index Fund (NYSEMKT: FBT)fool.com - October 22 at 3:06 AMFirst Trust Energy Infrastructure Fund Issues Notice Regarding October 2022 Distributionmarkets.buffalonews.com - October 17 at 4:24 PM2 Health Care And Biotech ETFs Poised For Robust Returns This Yearinvesting.com - June 9 at 5:09 AMBest Biotech ETFs for Q3 2022finance.yahoo.com - June 4 at 1:51 AMBest Biotech ETFs for Q2 2022finance.yahoo.com - February 25 at 10:32 PMGet Ready for a Biotech ETF Comebackfinance.yahoo.com - February 20 at 9:07 PMBiotech ETFs plunge in the first month of 2022, some down nearly 30%seekingalpha.com - January 27 at 6:05 PMFBT Makes Bullish Cross Above Critical Moving Averagenasdaq.com - December 23 at 7:28 PMIs First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?msn.com - October 25 at 7:43 AMWhy ETFs may be the best way to bet on the future of biotechtheglobeandmail.com - October 12 at 6:51 AMFBT's Holdings Imply 19% Gain Potentialnasdaq.com - September 2 at 5:10 PMFBT Crosses Below Key Moving Average Levelnasdaq.com - August 16 at 4:51 PMHow The Pieces Add Up: FBT Targets $208nasdaq.com - August 12 at 2:34 PMQ2 Growth 'Nothing Short Of Virtuous': Economistmsn.com - July 29 at 7:14 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option ActivityTop 3 Stocks Bought By Members of Congress In the First QuarterMarch 25, 2024 8:55 AMView Top 3 Stocks Bought By Members of Congress In the First Quarter3M Spun Off Its Health Division, Is It Still A Buy?April 4, 2024 7:47 AMView 3M Spun Off Its Health Division, Is It Still A Buy?Taiwan Semiconductor Earnings: AI Dominance and Future OutlookApril 19, 2024 7:06 AMView Taiwan Semiconductor Earnings: AI Dominance and Future OutlookMarketBeat Week in Review – 3/25-3/29March 30, 2024 7:00 AMView MarketBeat Week in Review – 3/25-3/29All Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Brookdale Senior LivingNYSE:BKDBrookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.Mack-Cali RealtyNYSE:CLIMack-Cali Realty Corp. is a real estate investment trust, which owns and operates a real estate portfolio comprised predominantly of Class A office and office flex properties located primarily in the Northeast. It operates through the following two segments: Commercial and Other Real Estate, and Multi-Family Real Estate and Services. The Commercial and Other Real Estate and Multi-Family Real Estate Portfolio segments provides leasing, property management, acquisition, development, construction, and tenant-related services. The company was founded in 1949 and is headquartered in Jersey City, NJ.First Trust NYSE Arca Biotechnology Index FundNYSEARCA:FBTThe First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is managed by First Trust. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.